Eli Lilly is partnering with Camurus, a company with technology that extends how long an injectable drug lasts in the body, ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera ... target collaboration and license agreement with Eli Lilly and Company (“Lilly”) targeting diabetes ...

Sidekick is also working with a number of other pharma companies on companion ... and other chronic conditions. The new Lilly alliance is one of three that Sidekick expects to announce in the ...

demonstrati Eli Lilly and Company (NYSE: LLY) and Purdue University announced today a significant expansion of their long-standing alliance, with Lilly's planned investment of up to $250 million ...

The addition of postsurgical atezolizumab immunotherapy to standard-of-care chemotherapy in patients with stage III deficient ...

By Priya Kalia, SciTribe and Miranda Weston-Smith, BioBeat.

About 15% of colon cancers are dMMR, which confers resistance to chemotherapy. ICIs have FDA approval for metastatic dMMR ...

ImmunoGenAlmost four years after backing out of an antibody-drug conjugate (ADC) alliance with ImmunoGen, Eli Lilly ... therapy in 2019. Lilly is thought to be the first pharma company to sign ...

Even years later, patients whose symptoms were initially dismissed experience distrust and uncertainty with clinicians.

TeamSense ranked all 50 states and the District of Columbia by their level of search interest in manufacturing topics.